Search

Your search keyword '"Hofmann W. -K."' showing total 504 results

Search Constraints

Start Over You searched for: Author "Hofmann W. -K." Remove constraint Author: "Hofmann W. -K."
504 results on '"Hofmann W. -K."'

Search Results

126. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

127. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial

128. S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS

131. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasm with eosinophilia

132. Detection of Aspergillus DNA and azole resistance mutations from BAL samples of immunocompromised patients and from serially diluted Aspergillus fumigatus conidia in BAL fluid sensitivity comparison of two molecular assays

135. The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia

136. Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised Patients

137. Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients

138. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

139. CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE

140. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-beta-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study

141. Identification of invasive fungal infections in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA microarray

142. Performance of combinations of Aspergillus PCR, multifungal DNA microarray, galactomannan, 1,3-beta-D-glucan and Aspergillus azole resistance PCRs in blood and BAL samples for diagnosis and characterization of invasive fungal infections in haematological patients

143. Low prevalence of cyp51A key mutations in Aspergillus fumigatus in Germany in primary clinical samples (blood, BAL, biopsies, CSF) and isolates of immunocompromised patients

144. Identification of invasive fungal diseases in immunocompromised patients by combining anAspergillusspecific PCR with a multifungal DNA-microarray from primary clinical samples

146. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

147. Dosage effect of zero to three functional LBR-genes in vivo and in vitro

149. Detection of fungal DNA in Aspergillus PCR-negative tissue biopsy samples from immunocompromised hematological patients using DNA microarray technology improves diagnosis of invasive fungal infections (IFI)

150. Aspergillus specific PCR of specimens more adequately representing the infectious localization such as bronchoalveolar lavage, cerebrospinal fluid or tissue/effusion samples are superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis

Catalog

Books, media, physical & digital resources